Anacetrapib vs Placebo Anacetrapib: Number of Participants With Major Vascular Event

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

Measures 6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

Measure	Value	95% interval, lower	95% interval, upper	Method	Source
Risk in group 1	0.136	0.13	0.141	wilson	ClinicalTrials.gov
Risk in group 2	0.145	0.14	0.151	wilson	ClinicalTrials.gov
Risk difference, group 1 minus group 2	-0.0096	-0.0174	-0.00179	newcombe hybrid score	ClinicalTrials.gov
Risk ratio, group 1 over group 2	0.934	0.884	0.987	log	ClinicalTrials.gov
Odds ratio, group 1 over group 2	0.924	0.866	0.985	log	ClinicalTrials.gov
Number needed to treat, for one fewer participant with the outcome on Anacetrapib than on Placebo Anacetrapib	104	57.4	559	from the risk difference interval	ClinicalTrials.gov

Groups 2

Group 2 names the comparator: placebo.

Group	Title	Description	With the outcome	Analysed	ClinicalTrials.gov code	Source
Group 1	Anacetrapib	Anacetrapib: 100mg daily	2,068	15,225	OG000	ClinicalTrials.gov
Group 2	Placebo Anacetrapib	Placebo anacetrapib: 1 tablet daily	2,214	15,224	OG001	ClinicalTrials.gov

Outcome 5

Field	Value	Source
Type	SECONDARY	ClinicalTrials.gov
Title	Number of Participants With Major Vascular Event	ClinicalTrials.gov
Description	Major vascular events (defined as coronary death, myocardial infarction, coronary revascularization or presumed ischaemic stroke).~Secondary assessments involve intention-to-treat comparisons among all randomized participants of the effects of allocation to anacetrapib versus placebo during the scheduled treatment period	ClinicalTrials.gov
Time frame	Randomized treatment phase during median follow-up period of 4.1years	ClinicalTrials.gov
Population		ClinicalTrials.gov

Trial 8

Field	Value	Source
Title	REVEAL: Randomized EValuation of the Effects of Anacetrapib Through Lipid-modification	ClinicalTrials.gov
NCT number	NCT01252953	ClinicalTrials.gov
Phases	PHASE3	ClinicalTrials.gov
Conditions	Atherosclerotic Cardiovascular Disease	ClinicalTrials.gov
Interventions	Anacetrapib, Placebo anacetrapib	ClinicalTrials.gov
Lead sponsor	University of Oxford	ClinicalTrials.gov
Results first posted	2018-05-04	ClinicalTrials.gov
Results on ClinicalTrials.gov	https://clinicaltrials.gov/study/NCT01252953?tab=results	ClinicalTrials.gov

Source 4

Field	Value	Source
Release	trial-comparisons-2026-03-23-0.1.0	ClinicalTrials.gov
Release manifest SHA-256	f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57	ClinicalTrials.gov
AACT copy	2026-03-23	ClinicalTrials.gov
Tables read	outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet	ClinicalTrials.gov

The same record as JSON

Release trial-comparisons-2026-03-23-0.1.0

ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.